Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology.

Yu K, Hyun N, Fetterman B, Lorey T, Raine-Bennett TR, Zhang H, Stamps RE, Poitras NE, Wheeler W, Befano B, Gage JC, Castle PE, Wentzensen N, Schiffman M.

J Natl Cancer Inst. 2018 Apr 11. doi: 10.1093/jnci/djy044. [Epub ahead of print]

PMID:
29659930
2.

Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy.

Demarco M, Cheung LC, Kinney WK, Wentzensen N, Lorey TS, Fetterman B, Poitras NE, Befano B, Castle PE, Schiffman M.

J Low Genit Tract Dis. 2018 Apr;22(2):97-103. doi: 10.1097/LGT.0000000000000382.

3.

Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing.

Demarco M, Carter-Pokras O, Hyun N, Castle PE, He X, Dallal CM, Chen J, Gage JC, Befano B, Fetterman B, Lorey T, Poitras N, Raine-Bennett TR, Wentzensen N, Schiffman M.

J Clin Microbiol. 2018 Apr 25;56(5). pii: e01910-17. doi: 10.1128/JCM.01910-17. Print 2018 May.

PMID:
29491018
4.

Vascular parameters continue to decrease post-exposure with simultaneous, but not individual exposure to BPA and hypoxia in zebrafish larvae.

Cypher AD, Fetterman B, Bagatto B.

Comp Biochem Physiol C Toxicol Pharmacol. 2018 Apr;206-207:11-16. doi: 10.1016/j.cbpc.2018.02.002. Epub 2018 Feb 15.

PMID:
29454160
5.

Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21-39 Years.

Silver MI, Gage JC, Schiffman M, Fetterman B, Poitras NE, Lorey T, Cheung LC, Katki HA, Locke A, Kinney WK, Castle PE.

Cancer Prev Res (Phila). 2018 Mar;11(3):165-170. doi: 10.1158/1940-6207.CAPR-17-0293. Epub 2018 Feb 5.

PMID:
29437696
6.

Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women.

Clarke MA, Gradissimo A, Schiffman M, Lam J, Sollecito CC, Fetterman B, Lorey T, Poitras N, Raine-Bennett TR, Castle PE, Wentzensen N, Burk RD.

Clin Cancer Res. 2018 May 1;24(9):2194-2202. doi: 10.1158/1078-0432.CCR-17-3251. Epub 2018 Feb 2.

PMID:
29420222
7.

Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer.

Clarke MA, Fetterman B, Cheung LC, Wentzensen N, Gage JC, Katki HA, Befano B, Demarco M, Schussler J, Kinney WK, Raine-Bennett TR, Lorey TS, Poitras NE, Castle PE, Schiffman M.

J Clin Oncol. 2018 Apr 20;36(12):1184-1191. doi: 10.1200/JCO.2017.75.3442. Epub 2018 Jan 22.

PMID:
29356609
8.

Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting.

Rendle KA, Schiffman M, Cheung LC, Kinney WK, Fetterman B, Poitras NE, Lorey T, Castle PE.

Prev Med. 2018 Apr;109:44-50. doi: 10.1016/j.ypmed.2017.12.023. Epub 2017 Dec 27.

PMID:
29288782
9.

Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records.

Landy R, Cheung LC, Schiffman M, Gage JC, Hyun N, Wentzensen N, Kinney WK, Castle PE, Fetterman B, Poitras NE, Lorey T, Sasieni PD, Katki HA.

Prev Med. 2018 Jun;111:429-435. doi: 10.1016/j.ypmed.2017.12.004. Epub 2017 Dec 6.

10.

Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer: An Observational Cohort Study.

Castle PE, Kinney WK, Xue X, Cheung LC, Gage JC, Zhao FH, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Katki HA, Schiffman M.

Ann Intern Med. 2018 Jan 2;168(1):20-29. doi: 10.7326/M17-1609. Epub 2017 Nov 28.

PMID:
29181509
11.

Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.

Schiffman M, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler J, Katki HA, Castle PE.

J Natl Cancer Inst. 2018 May 1;110(5):501-508. doi: 10.1093/jnci/djx225.

PMID:
29145648
12.

Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.

Demarco M, Lorey TS, Fetterman B, Cheung LC, Guido RS, Wentzensen N, Kinney WK, Poitras NE, Befano B, Castle PE, Schiffman M.

J Low Genit Tract Dis. 2017 Oct;21(4):261-267. doi: 10.1097/LGT.0000000000000343.

13.

Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records.

Cheung LC, Pan Q, Hyun N, Schiffman M, Fetterman B, Castle PE, Lorey T, Katki HA.

Stat Med. 2017 Sep 30;36(22):3583-3595. doi: 10.1002/sim.7380. Epub 2017 Jun 28.

PMID:
28660629
14.

Why does cervical cancer occur in a state-of-the-art screening program?

Castle PE, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler J, Katki HA, Schiffman M.

Gynecol Oncol. 2017 Sep;146(3):546-553. doi: 10.1016/j.ygyno.2017.06.003. Epub 2017 Jun 10.

PMID:
28606721
15.

Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?

Fokom Domgue J, Schiffman M, Wentzensen NH, Gage JC, Castle PE, Raine-Bennett TR, Fetterman B, Lorey T, Poitras NE, Befano B, Xie Y, Miachon LS, Dean M.

J Clin Microbiol. 2017 Aug;55(8):2348-2355. doi: 10.1128/JCM.00492-17. Epub 2017 May 17.

16.

The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.

Silver MI, Schiffman M, Fetterman B, Poitras NE, Gage JC, Wentzensen N, Lorey T, Kinney WK, Castle PE.

Cancer. 2016 Dec 1;122(23):3682-3686. doi: 10.1002/cncr.30277. Epub 2016 Sep 22.

17.

A cohort study of cervical screening using partial HPV typing and cytology triage.

Schiffman M, Hyun N, Raine-Bennett TR, Katki H, Fetterman B, Gage JC, Cheung LC, Befano B, Poitras N, Lorey T, Castle PE, Wentzensen N.

Int J Cancer. 2016 Dec 1;139(11):2606-15. doi: 10.1002/ijc.30375. Epub 2016 Aug 26.

18.

Response.

Wentzensen N, Fetterman B, Castle P, Schiffman M, Wood S, Tokugawa D, Bodelon C, Poitras N, Lorey T, Kinney W.

J Natl Cancer Inst. 2015 Dec 27;108(2). pii: djv390. doi: 10.1093/jnci/djv390. Print 2016 Feb. No abstract available.

19.

A joint model of persistent human papillomavirus infection and cervical cancer risk: Implications for cervical cancer screening.

Katki HA, Cheung LC, Fetterman B, Castle PE, Sundaram R.

J R Stat Soc Ser A Stat Soc. 2015 Oct 1;178(4):903-923. Epub 2015 Mar 17.

20.

p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women.

Wentzensen N, Fetterman B, Castle PE, Schiffman M, Wood SN, Stiemerling E, Tokugawa D, Bodelon C, Poitras N, Lorey T, Kinney W.

J Natl Cancer Inst. 2015 Sep 15;107(12):djv257. doi: 10.1093/jnci/djv257. Print 2015 Dec.

21.

A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results.

Schiffman M, Vaughan LM, Raine-Bennett TR, Castle PE, Katki HA, Gage JC, Fetterman B, Befano B, Wentzensen N.

Gynecol Oncol. 2015 Sep;138(3):573-8. doi: 10.1016/j.ygyno.2015.06.040. Epub 2015 Jul 4.

22.

Response.

Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, Poitras NE, Lorey T, Cheung LC, Kinney WK.

J Natl Cancer Inst. 2014 Dec 26;107(1):390. doi: 10.1093/jnci/dju390. Print 2015 Jan. No abstract available.

23.

Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection.

Gage JC, Katki HA, Schiffman M, Fetterman B, Poitras NE, Lorey T, Cheung LC, Castle PE, Kinney WK.

Int J Cancer. 2015 Apr 1;136(7):1665-71. doi: 10.1002/ijc.29143. Epub 2014 Sep 2.

24.

Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening.

Wentzensen N, Fetterman B, Tokugawa D, Schiffman M, Castle PE, Wood SN, Stiemerling E, Poitras N, Lorey T, Kinney W.

Cancer Cytopathol. 2014 Dec;122(12):914-20. doi: 10.1002/cncy.21473. Epub 2014 Aug 12.

25.

The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.

Gage JC, Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Behrens C, Sharma A, Zhao FH, Cuzick J, Yang ZH, Kinney WK.

Cancer Cytopathol. 2014 Nov;122(11):842-50. doi: 10.1002/cncy.21463. Epub 2014 Jul 9.

26.

Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.

Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, Poitras NE, Lorey T, Cheung LC, Kinney WK.

J Natl Cancer Inst. 2014 Jul 18;106(8). pii: dju153. doi: 10.1093/jnci/dju153. Print 2014 Aug.

27.

Analytic and clinical performance of cobas HPV testing in anal specimens from HIV-positive men who have sex with men.

Wentzensen N, Follansbee S, Borgonovo S, Tokugawa D, Sahasrabuddhe VV, Chen J, Lorey TS, Gage JC, Fetterman B, Boyle S, Sadorra M, Tang SD, Darragh TM, Castle PE.

J Clin Microbiol. 2014 Aug;52(8):2892-7. doi: 10.1128/JCM.03517-13. Epub 2014 Jun 4.

28.

Cervical cancer rates after the transition from annual Pap to 3-year HPV and Pap.

Dinkelspiel H, Fetterman B, Poitras N, Kinney W, Cox JT, Lorey T, Castle PE.

J Low Genit Tract Dis. 2014 Jan;18(1):57-60. doi: 10.1097/LGT.0b013e31829325c3.

PMID:
24022057
29.

Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men.

Schwartz LM, Castle PE, Follansbee S, Borgonovo S, Fetterman B, Tokugawa D, Lorey TS, Sahasrabuddhe VV, Luhn P, Gage JC, Darragh TM, Wentzensen N.

J Infect Dis. 2013 Dec 1;208(11):1768-75. doi: 10.1093/infdis/jit374. Epub 2013 Aug 1.

30.

Risk of cervical precancer and cancer in women with cervical intraepithelial neoplasia grade 1 on endocervical curettage.

Fukuchi E, Fetterman B, Poitras N, Kinney W, Lorey T, Littell RD.

J Low Genit Tract Dis. 2013 Jul;17(3):255-60. doi: 10.1097/LGT.0b013e31826ca4d9.

PMID:
23733162
31.

Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S78-84. doi: 10.1097/LGT.0b013e31828543c5.

32.

Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.

Katki HA, Gage JC, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S69-77. doi: 10.1097/LGT.0b013e31828543b1.

33.

Five-year risk of CIN 3+ to guide the management of women aged 21 to 24 years.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S64-8. doi: 10.1097/LGT.0b013e3182854399.

34.

Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S56-63. doi: 10.1097/LGT.0b013e318285437b.

35.

Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S50-5. doi: 10.1097/LGT.0b013e3182854282.

36.

Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S43-9. doi: 10.1097/LGT.0b013e3182854269.

37.

Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S36-42. doi: 10.1097/LGT.0b013e3182854253.

38.

Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S28-35. doi: 10.1097/LGT.0b013e318285423c.

39.

A study of borderline positive Hybrid Capture 2 tests in the Kaiser Permanente Northern California cervical screening program: evidence against retesting.

Lamere BJ, Castle PE, Fetterman B, Poitras N, Stanley M, Shieh J, Lorey T, Kinney W, Schiffman M.

J Virol Methods. 2013 Apr;189(1):77-9. doi: 10.1016/j.jviromet.2013.01.011. Epub 2013 Feb 4. No abstract available.

40.

Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact.

Dunne EF, Klein NP, Naleway AL, Baxter R, Weinmann S, Riedlinger K, Fetterman B, Steinau M, Scarbrough MZ, Gee J, Markowitz LE, Unger ER.

Cancer Causes Control. 2013 Feb;24(2):403-7. doi: 10.1007/s10552-012-0085-9. Epub 2013 Jan 5.

PMID:
23292130
41.

Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men.

Sahasrabuddhe VV, Castle PE, Follansbee S, Borgonovo S, Tokugawa D, Schwartz LM, Lorey TS, LaMere BJ, Gage JC, Fetterman B, Boyle S, Sadorra M, Tang SD, Darragh TM, Wentzensen N.

J Infect Dis. 2013 Feb 1;207(3):392-401. doi: 10.1093/infdis/jis694. Epub 2012 Nov 16.

42.

A comparison of human papillomavirus genotype-specific DNA and E6/E7 mRNA detection to identify anal precancer among HIV-infected men who have sex with men.

Castle PE, Follansbee S, Borgonovo S, Tokugawa D, Schwartz LM, Lorey TS, LaMere B, Gage JC, Fetterman B, Darragh TM, Rodriguez AC, Wentzensen N.

Cancer Epidemiol Biomarkers Prev. 2013 Jan;22(1):42-9. doi: 10.1158/1055-9965.EPI-12-0984. Epub 2012 Nov 15.

43.

Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM.

Wentzensen N, Follansbee S, Borgonovo S, Tokugawa D, Schwartz L, Lorey TS, Sahasrabuddhe VV, Lamere B, Gage JC, Fetterman B, Darragh TM, Castle PE.

AIDS. 2012 Nov 13;26(17):2185-92. doi: 10.1097/QAD.0b013e328359f255.

44.

A general binomial regression model to estimate standardized risk differences from binary response data.

Kovalchik SA, Varadhan R, Fetterman B, Poitras NE, Wacholder S, Katki HA.

Stat Med. 2013 Feb 28;32(5):808-21. doi: 10.1002/sim.5553. Epub 2012 Aug 2.

45.

Interrater agreement of anal cytology.

Darragh TM, Tokugawa D, Castle PE, Follansbee S, Borgonovo S, LaMere BJ, Schwartz L, Gage JC, Fetterman B, Lorey T, Wentzensen N.

Cancer Cytopathol. 2013 Feb;121(2):72-8. doi: 10.1002/cncy.21218. Epub 2012 Jul 18.

46.

Safety against cervical precancer and cancer following negative human papillomavirus and Papanicolaou test results in human immunodeficiency virus-infected women.

Castle PE, Fetterman B, Poitras N, Lorey T, Kinney W.

Arch Intern Med. 2012 Jul 9;172(13):1041-3. doi: 10.1001/archinternmed.2012.1744. No abstract available.

PMID:
22641193
47.

Screening history preceding a diagnosis of cervical cancer in women age 65 and older.

Dinkelspiel H, Fetterman B, Poitras N, Kinney W, Cox JT, Lorey T, Castle PE.

Gynecol Oncol. 2012 Aug;126(2):203-6. doi: 10.1016/j.ygyno.2012.04.037. Epub 2012 May 2.

PMID:
22561038
48.

Comparison of the cobas Human Papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests.

Gage JC, Sadorra M, Lamere BJ, Kail R, Aldrich C, Kinney W, Fetterman B, Lorey T, Schiffman M, Castle PE; PaP Cohort Study Group.

J Clin Microbiol. 2012 Jan;50(1):61-5. doi: 10.1128/JCM.05989-11. Epub 2011 Nov 9.

49.

Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.

Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S, Castle PE.

Lancet Oncol. 2011 Jul;12(7):663-72. doi: 10.1016/S1470-2045(11)70145-0. Epub 2011 Jun 16. Erratum in: Lancet Oncol. 2011 Aug;12(8):722.

50.

Variable risk of cervical precancer and cancer after a human papillomavirus-positive test.

Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Schiffman M, Demuth F, Kinney W.

Obstet Gynecol. 2011 Mar;117(3):650-6. doi: 10.1097/AOG.0b013e318209da59.

PMID:
21343769

Supplemental Content

Loading ...
Support Center